Prior authorization for infusion, oncology, and specialty drugs across medical and pharmacy rails

Drug PA is the single hardest category to get right because the same drug can route through the medical benefit, the pharmacy benefit manager, or a specialty pharmacy depending on administration site and plan benefit design. An infusion of Remicade in the office is a medical-benefit J-code PA. Self-injected Humira is a PBM PA. Specialty Rx at Accredo, CVS Specialty, or Optum Specialty is yet another path. This page walks all three rails.

Infusion therapy and biologics

Office-administered biologics route through the medical benefit on a J-code. The volume categories: TNF-alpha inhibitors (Remicade/Inflectra J1745/Q5121, Simponi Aria J1602), interleukin inhibitors (Stelara J3358, Skyrizi J2327, Tremfya J1628, Cosentyx J3245, Taltz J1834), integrin inhibitors (Entyvio J3380), and B-cell inhibitors (Rituxan J9310, Kesimpta). Each drug has a plan-specific step-therapy requirement: most plans require documented failure or intolerance of TNF-alpha inhibitors before approving newer mechanism drugs, and MTX or azathioprine failure before biologics in many indications.

IVIG (J1569 Gammagard, J1459 Privigen, J1561 Gamunex, J1568 Octagam) requires diagnosis-specific PA: CIDP, PID, ITP, and neurology indications all have different packet requirements. Most plans require IgG level, diagnosis documentation, and failed alternative therapies. Subcutaneous IG (Hizentra, Cuvitru) typically routes through the specialty pharmacy.

Enzyme replacement therapies (Cerezyme, Fabrazyme, Myozyme, Elaprase, Kanuma) are ultra-high-cost and require rare-disease documentation. Xolair for asthma (J2357) and Nucala, Fasenra, Tezspire for severe asthma each have type-2 inflammation documentation requirements (eosinophils, IgE levels).

Medical oncology: chemotherapy, immunotherapy, targeted therapy

Oncology PA is typically treatment-plan-wide rather than per-infusion. A chemotherapy regimen gets a single treatment plan PA that covers all cycles at the specified doses. Changes to the regimen (dose reduction, drug swap, progression-driven change) trigger a PA amendment. Modern oncology PA runs on pathway-based review: Optum Oncology Pathways, eviCore oncology pathways, NCCN-aligned payer programs, and direct-payer oncology review.

Immunotherapy (Keytruda J9271, Opdivo J9299, Yervoy J9228, Tecentriq J9022, Imfinzi J9173, Jemperli J9272) PA requires specific-indication documentation matching the FDA label, biomarker results (PD-L1 expression, MSI-H, TMB-H), and prior therapy lines. CAR-T cell therapy (Q2042 Yescarta, Q2041 Kymriah, Q2053 Tecartus, Q2054 Abecma, Q2055 Breyanzi, Q2056 Carvykti) PA is a separate workflow with mandatory treatment-center certification and a specific intake process.

Targeted therapy including oral oncolytics (Imbruvica, Tagrisso, Tafinlar, Lynparza, Calquence, Jakafi) mostly routes through specialty pharmacy with PBM/specialty PA, plus a medical review at many plans. Molecular testing (FoundationOne, Guardant, Caris) often has separate PA with its own criteria.

Radiation oncology

External beam radiation PA covers IMRT (77301, 77338), IGRT (77385, 77386), SBRT (77373, 32701), and proton therapy (77520-77525). Payers delegate radonc PA to eviCore oncology or Optum for several lines. IMRT requires documentation that the specific site/anatomy requires the dose conformality that IMRT provides over 3DCRT. SBRT requires the specific indication (lung, liver, spine, prostate) with imaging and tumor-board documentation. Proton therapy remains a contentious PA category: several commercial plans cover only specific pediatric, CNS, and select adult indications; others cover more broadly. The NAPT and ASTRO guidelines are referenced in payer policy.

Brachytherapy (prostate seed implant 77778, HDR 77317-77318) has its own PA pattern with source-specific documentation. TheraSphere and SIR-Spheres (Y-90 37242) require hepatic tumor documentation and multidisciplinary review.

Specialty pharmacy drugs

Specialty pharmacy (Accredo, CVS Specialty, OptumRx Specialty, Walgreens Specialty) handles drugs billed to the PBM benefit. The PA path is PBM-based with specialty-pharmacy coordination. Drug categories: self-injected biologics (Humira, Enbrel, Cimzia, Dupixent), oral oncolytics, multiple sclerosis drugs (Ocrevus, Tysabri, Kesimpta, Ponvory, Zeposia), hepatitis C DAAs (Mavyret, Epclusa, Vosevi), and growth hormone (Sogroya, Norditropin).

The operational complexity is coordination: the practice writes the prescription, the PBM processes the PA, the specialty pharmacy dispenses, and the patient receives at home. A PA rejection at the PBM blocks the specialty pharmacy from dispensing. Flexbone runs the PA from the practice side, resolves PBM rejections, and confirms the specialty pharmacy can dispense before the patient's run-out date.

Medical vs PBM vs specialty pharmacy rails

UnitedHealthcare routes many drugs through the Optum specialty-pharmacy program. Aetna uses CVS Specialty. Anthem/Elevance uses CarelonRx (formerly IngenioRx) and Accredo. Cigna uses Evernorth/Accredo. Humana uses Humana Specialty Pharmacy. See commercial payers for the full map.

Oncology EHRs and infusion platforms

• Oncology EHRs: Flatiron OncoEMR, iKnowMed (McKesson/Ontada), Aria (Varian), MOSAIQ (Elekta), Varian Eclipse.
• Infusion platforms: IntelliDose (Cerner), Cato, OncoEMR.
• Radiation oncology: Aria, MOSAIQ.
• Specialty pharmacy: CareTend (Mediware/WellSky), Opus (CarepathRx), Pharmacy-specific.
• See outpatient EHR PA for multi-specialty.

How Flexbone handles drug PA

Flexbone runs drug PA on dual rails: the medical-benefit agent submits to the plan directly for J-code PA; the PBM/specialty agent submits to the PBM and coordinates with the specialty pharmacy. For oncology, the treatment-plan-wide PA is submitted once per regimen and re-submitted on change. For CAR-T and proton therapy, Flexbone handles the long-packet assembly across multiple specialists. See PA workflow and the platform.